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ABSTRACT

The present invention relates to methods and compositions
for eliciting an immune response against bovine viral
epitopes. The methods comprise combining at least one heat
Shock protein with at least one bovine viral epitope to form
a purified epitope/heat Shock protein complex and adminis
tration of an immune System Stimulating amount of the
purified epitope/heat shock protein complex. The composi
tions comprise, a purified epitope/heat Shock protein com
pleX comprising at least one bovine viral epitope complexed
with at least one heat shock protein, and a pharmaceutically
acceptable carrier, diluent or excipient.
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METHODS AND COMPOSITIONS FOR
PROTECTION AGAINST BOVINE WRAL
DESEASES
BACKGROUND

0001. This invention relates to compositions and methods
of immunizing animals against bovine viral diseases. In
particular, this invention relates to compositions comprising
bovine Viral epitopes complexed to a heat shock protein and
use of Said compositions to immunize animals. More par
ticularly, this invention relates to compositions comprising
bovine viral epitopes complexed to heat shock glycoprotein
96 and the use of Said compositions to immunize animals.
0002) Numerous vaccine preparations utilizing killed

(inactivated) or live attenuated viruses are currently avail

able. Inactivated vaccines are prepared by killing the virus,
for example, by heat, irradiation or chemical treatment.
Many inactivated vaccines have not been Satisfactory Since
they fail to induce humoral immunity of long duration, and
are incapable of inducing a Satisfactory cell-mediated
immune response. Attenuated vaccines are prepared by a
large number of passages on homologous or heterologous
cells. These passages result in unknown mutations/deletions
which reduce the pathogenicity of the virus. Alternatively,
attenuated viruses can be produced by genetic engineering.

For example, Rijsewijk (U.S. Pat. No. 5,676.951) teaches
the use of mutant bovine herpesvirus 1(BHV 1) containing

either a naturally occurring or induced deletion in the
glycoproteing gene. Attenuated virus vaccines give better
protection than do killed virus Vaccines, however, attenuated
vaccines Set up latent infections in vaccinated animals which
may lead to disease outbreak if the virus reactivates and
mutates back to a virulent form.

0003) To overcome the shortcomings of killed or attenu
ated virus vaccines, attempts have been made to provide
vaccines based on viral proteins or nucleotide Sequences

encoding viral proteins. Israel et al. (Vaccine, 6:349-356,
1988) discloses the use of a BHV 1 glycoprotein vaccine.

Although administration of this vaccine resulted in high
antibody titers, it did not confer resistance to an intra nasal
challenge of BHV 1.
0004. Because of the ability of many viruses to spread
from cell to cell, cell mediated immunity, Specifically that

provided by virus-specific cytotoxic T lymphocytes (CTLs),

is equally if not more important than neutralizing antibodies
in protecting the animal from infection. To be recognized by
CTLS, an infected cell must present the viral peptides in
association with the Major Histocompatibility Complex

(MHC) class I molecules on its surface. These CTL peptide

epitopes are generated by proteoSomal processing of viral
proteins, and the epitopes are translocated from the cytosol
into the lumen of the endoplasmic reticulum by Specialized
transporters called "transporters associated with antigen

processing” (TAP). The 8 to 10-mer CTL peptide epitopes
asSociate and form a stable complex with the class I heavy
chain and the f-microglobulin in the endoplasmic reticu
lum. The family of peptides bound by a particular class I
molecule is characterized by the presence of a restricted
number of "anchor amino acid residues, at particular posi
tions in the peptide. The "anchor residues and their position
in the peptides bound by a particular class I allelic product
constitute the “allele-specific peptide motif (ASPM). Thus,
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peptides containing ASPMs are especially effective in elic
iting cell mediated immune responses. The extreme poly
morphism in the MHC, however, can result in a large
number of possible alleles, and hence ASPMs. Thus, limit
ing their potential therapeutic value.
0005 The discovery of MHC Supertypes in humans pre
sents a possible solution to the problem presented by MHC
polymorphism. Supertypes are a group of class I alleles
which share the same or similar ASPMs. The term super
motif is used to refer to such motifs which bind to a large

number of different class I alleles (Sette and Sidney, Curr.
Opin. Immunol., 10:478-482, 1998). By using peptides

containing Supermotifs, it is possible to bind epitopes to a
wide variety of MHC class I molecules, and hence elicit a
CTL response in a large percentage of individuals in a
population.
0006. It is now known that there are other transporters
involved in epitope presentation. These transporters are
members of the class of proteins known as heat shock

proteins (HSPs) (See, Schild et al., Curr. Opin. Immunol,
11:109-113, 1999). Heat shock proteins are a group of
proteins whose presence was originally associated with cell
StreSS, particularly increased temperature. Three major fami
lies of HSPs hsp60, hsp70 and hsp90 have been identified on

the basis of their molecular weights (Welch, Scientific
American, 56-64, May 1993). Many members of these
families have been found to be induced in response to
Stressful Stimuli in addition to heat StreSS Such as nutrient

deprivation, metabolic disruption and intracellular patho

gens (Welch, Scientific American, 56-64, May 1993; Craig,
Science, 260:1902-1903, 1993; Gething, et al., Nature,
355:33-45, 1992; Young, Ann. Rev. Immunol., 8:401-420,

1990; Lindquist et al., Ann. Rev. Genet., 22:631-677, 1988).
0007 Heat shock proteins are highly conserved among

species. For example, hsp70 shows 74% nucleotide
Sequence homology between yeast and Drosophila, and 85%

Sequence homology between Drosophila and mice (Moranet
al., Can. J Biochem. Cell Biol., 61:488-499, 1983). The
amino acid sequence of human hsp70 is 40% identical to E.
coli hsp70, dnaK, and 73% identical to Drosophila hsp70

(Hunt and Morimoto, Proc. Natl. Acad. Sci. USA, 82:6455
6459, 1985). Thus, the present invention contemplates the
use of HSPs not only within species (homologous HSP), but
also across species (heterologous HSPs).
0008. The evidence that HSPs are involved in immune
system function came from the observation that HSPs iso
lated from cancer cells or virus infected cells induced

protective immunity or cytotoxic T lymphocytes (CTL) to
the cognate tumor or viral antigen. In contrast, HSPS isolated
from non-cancerous or uninfected cells elicited no immune

response. This, combined with the finding that the HSPs do
not show tumor-associated DNA polymorphism, Suggested
that HSPs were not immunogenic themselves, but served as
chaperones for peptides formed during antigen processing

(Suto and Srivastava, Science, 269:1585-1588, 1995). Mem

bers of all three HSP families, hsp60, hsp70 and hsp90, have
been shown to play a role in Stimulation of cell mediated

immunity (Könen-Waisman et al., J. Infect. Dis., 179:403

413, 1999; Schild et al., Curr. Opin. Immunol., 11:109-113,
1999; Blachere et al., J. Exp. Med., 186:1315-1322, 1997;

Heike et al., J. Leukoc. Biol., 60:153-158, 1996). It has been

Suggested that HSPS complexed with antigenic peptides are
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released from virus infected or cancerous cells by lysis of the
cells during infection or by the action of antibodies or
nonspecific effectors. The HSP/antigenic peptide complexes
are then taken up by macrophages or other specialized
antigen-presenting cells, possibly by a receptor mediated
mechanism. The complex is then routed to the endogenous
presentation pathway in the antigen presenting cell and is
displayed in the context of that cell's MHC class I, where it

is recognized by CTLS (Srivastava et al., Immunogenetics,

39:93-98, 1994; Suto and Srivastava, Science, 269:1585

1588, 1995). More recently, however, this suggestion has
been questioned (Schild et al., Curr. Opin. Immunol.,
11:109-113, 1999) based on antisense experiments in which

inhibition of gp96 expression failed to influence the ability

of cells to present peptides to CTLS (Lammert et al., Eur: J.
Immnol. 26:875-879, 1996). In addition, it has been found
that the HSPgp96 cannot bind peptides with charged amino
acids at P2 and P9 (Spee and Neefjes, Eur: J. Immunol.
27:2441-2449, 1997) and that gp96 has a hydrophobic
peptide binding domain (Wearsch et al., Biochemistry,
37:5709-5719 (1998) thus limiting its peptide binding.
0009 Glycoprotein 96 (gp96) is a member of the HSP90

are used to Stimulate cell mediated immunity. AS discussed
previously, attenuated viral vaccines are not without prob
lems. There is a need, therefore, for a composition that is
capable of eliciting a cell mediated response against bovine
viruses, but does not involve the use of a live virus. The

present invention meets that need.
0012. The present invention insures a T cell response by
utilizing the heat Shock protein gp96 as an adjuvant. The
gp96 protein is involved in the association of peptides with
the MHC type I presentation pathway. Presentation of the
antigen by the MHC class I complex is thought to be critical
for eliciting a cell-mediated immune response. The fact that
gp96 transferS peptides to the class I antigen presentation
pathway ensures that the peptide epitopes complexed to it
will be directed to the class I antigen presentation pathway.
Also, because only peptides are used, there is no problem
with virus reactivation and Shedding, down regulation of the
MHC class I surface molecules, and apoptosis of CD4 T
cells as is seen with modified live virus preparations that are
currently used to Stimulate cell mediated immunity against
BHV 1.

ment of cancer (U.S. Pat. Nos. 5.830,464, 5,837,251, 5,935,
98/34641). The same publications disclose the use of gp96/

0013 In addition, the method of obtaining epitope/heat
Shock protein complex from a transfected cell expressing a
BHV 1 protein alleviates the need for prior identification of
Specific CTL epitopes. In this method, the epitope/heat
Shock protein complex contains not only the peptides pre
Sented by the class I molecules of the transfectant, but also
the peptides presented by other class I alleles as well. The
epitope/heat Shock protein complex, therefore, can be used
to immunize animals with a different MHC background.
0014) Accordingly, among the aspects of the present
invention is to provide a method for eliciting an immune
response in an animal to a bovine virus comprising, com
bining a bovine Viral epitope and a heat shock protein to
form a purified epitope/heat Shock protein complex and
administering an immune System Stimulating amount of Said
purified epitope/heat shock protein complex to an animal.
0015. Another aspect of the invention, is a composition
comprising at least one bovine viral epitope complexed to a
heat shock protein to form a purified epitope/heat shock
protein complex, and a pharmaceutically acceptable carrier,
diluent or excipient.
0016. In another aspect of the invention, the bovine viral
epitope contains an allele Specific peptide motif.
0017. In still another aspect of the invention, the bovine
Viral epitope contains a Supermotif.
0018. In yet another aspect of the invention, the allele
Specific peptide motif is Selected from the group consisting

diseases in humans. Srivastava, however, does not teach or

of BoLA-A11, BoLA-A20, BoLA-HD1, BoLA-HD6, and

family which is found in the endoplasmic reticulum. Gly
coprotein 96 preparations isolated from cells expressing a
transfected cytosolic protein have been found to elicit spe

cific CTLS against that antigen (Arnold et al., J. Exp. Med.,
182:885-889, 1995). In virus infected cells, gp96 prepara
tions isolated from cells infected with vesicular stomatitis

virus (VSV) were found to contain VSV derived peptides
(Nieland et al., Proc. Natl. Acad. Sci. USA, 93:6135-6139,
1996). For vaccine production, it has been found that

gp96-peptide complexes can be generated in Vitro and that
these complexes elicit immunity by a mechanism apparently
identical to that Seen with in Vivo generated complexes.
0.010 Interest in gp96 as an aid to inducing an immune
response against an antigen comes from Studies which found
that immunization of mice with gp96 isolated from tumor
cells provided protection against a Subsequent challenge
with the tumor cells from which the gp96 was isolated

(Srivastava et al., Proc. Natl. Acad. Sci. USA, 83:3407-3411,
1986; Srivastava et al., Adv. Cancer Res., 62:153-177,

1993). Further studies demonstrated that immunization with

gp96 molecules from autologous tumor cells elicited CD4"

and CD8" T cell responses (CD=Cluster of Differentiation)
against the primary tumor and its metastasises (Tamura et
al., Science, 278:117-120, 1997. Srivastava teaches the use

of antigens bound to gp96 for the immunotherapeutic treat
576, 5,948,646 and PCT publications WO 97/10001, WO

antigen complexes to treat or prevent various infectious

Suggest the use of gp96 as an adjuvant to induce CTLS
against bovine viruses nor does he teach the use of Viral
sequences that contain ASPMs. In addition, Srivastava does
not show Stimulation of a humoral as well as a cell-mediated
response.
SUMMARY

0.011) To be effective, it is widely accepted that any
vaccine preparation must also Stimulate a cell mediated
immune response, and in particular, the activation of cyto
toxic T lymphocytes. Presently, attenuated virus Vaccines

BOLA-HD7.

0019. Yet another aspect of the invention provides a
method for producing a bovine viral CTL epitope/heat shock
protein complex by transfecting a cell with a nucleotide
Sequence encoding a bovine viral protein, inducing expres
Sion of the bovine viral epitope under conditions which also
induce expression of the heat Shock protein and isolating the
epitope/heat Shock protein complex from the cells.
0020 Still another aspect of the invention is a method for
producing a bovine viral epitope/heat Shock protein complex
comprising combining an isolated heat shock protein with at
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least one bovine viral epitope and isolating the complex
from the uncomplexed epitope and heat shock protein.
Definitions

0021
0022
0023
0024
0025
0026
0027
0028

HSP=heat shock protein
ASPM=allele specific peptide motif
BSA=bovine serum albumin
CTL=cytotoxic T lymphocyte
gp96=heat shock protein glycoprotein 96
BHV 1=bovine herpesvirus 1
B-gal=B-galactosidase
Triton X-100=t-Octylphenoxypolyethoxyetha

nol

0029. Tween-20=polyoxyethylenesorbitan monolau
rate

0030 CD=Cluster of Differentiation
0031 moi=multiplicity of infection
0032 pfu=placque-forming unit
0033 cpm=counts per minute
0034) FBS=fetal bovine serum
0035 PBMC=peripheral blood mononuclear cell
0.036 AS used herein, “epitope' means a single antigenic
determinant of an antigenic molecule that Stimulates a
Specific immune response and against which that response is
directed. AS used herein, the term includes not only the
determinant, but also the molecule or fragment of the
molecule which contains the determinant.

0037 AS used herein the term “purified epitope/heat
Shock protein complex’ means that the complex is separated
from the majority of cell proteins normally associated with
it or that the complex is synthesized in purified form. Purity
may be assayed by Standard methods, and will ordinarily be
at least about 50% pure, generally at least about 60% pure,
more generally at least about 70% pure, often at least about
75% pure, more often at least about 80% pure, typically at
least about 85% pure, more typically at least about 90%
pure, preferably at least about 95% pure, more preferably at
least about 98% pure, and most preferably, at least 99%
pure. The analysis may be weight or molar percentages,
evaluated, e.g., by gel Staining, spectrophotometry, or ter
minus labeling.
0.038. As used herein, "naive” refers to an animal or cell
that has not been previously exposed to the antigen in
question.
0039. As used herein, the term “epitope/heat shock pro
tein complex refers to a complex containing at least one
epitope and at least one heat shock protein.
DETAILED DESCRIPTION

0040 All publications, patents, patent applications and
other references cited in this application are herein incor
porated by reference in their entirety as if each individual

publication, patent, patent application or other reference
were specifically and individually indicated to be incorpo
rated by reference.
0041 Applicants have invented methods and composi
tions for eliciting an immune response in an animal to at
least one epitope of a bovine virus. In particular, at least one
epitope of a bovine virus is complexed to a heat shock
protein which is then administered to an animal in an amount

that stimulates a measurable immune response (immune
System stimulating amount). Methods for determining
Stimulation of the immune System are well known to those
of ordinary skill in the art. Methods include, but are not
limited to, the determination of circulating antibodies and/or
the presence of Specific cytotoxic T lymphocytes. Stimula
tion of CTLS is thought to be critical to providing immunity
to viruses.

0042. The complexes of the present invention can be
comprised of any combination of heat shock proteins and
epitopes of bovine viruses in any manner of binding asso
ciation. In one embodiment, an epitope is non-covalently
bound to a heat Shock protein. In another embodiment, the

epitope contains an allele-specific peptide motif (ASPM). In

yet another embodiment, the epitope contains a Supermotif.
Suitable heat shock proteins include members of the heat
Shock protein 60, heat shock protein 70, and heat shock
protein 90 families. The heat shock protein can be obtained

from the species to which it is to be administered (homolo
gous heat shock protein) or it can be from a different species
(heterologous heat shock protein). In one preferred embodi
ment, the heat shock protein used is glycoprotein 96 (gp96).

Glycoprotein 96 is a glycosylated member of the heat shock
protein 90 family.
0043 Any protein or peptide derived from the bovine
Virus of interest can be used in complex with a heat shock
protein. Examples of Viruses from which proteins can be
obtained include, but are not limited to, bovine viral diarrhea

Virus, bovine respiratory Syncytial virus, parainfluenza virus
III, bovine corona virus, and bovine rota virus. Particularly
useful are proteins and peptides containing allele-Specific

peptide motifs (ASPM). Preferred ASPMs include bovine
lymphocyte antigens (BoLA)-A11 (Hegde et al., Immuno
genetics, 42:302-303, 1995), BoLA-A20 (Bamford et al.,
Immunol Lett., 45:129, 1995) and BoLA-HD1, -HD6 and
-HD7 (Gaddum et al., Immunogenetics, 43:238, 1996).

Because the peptides usually presented by the MHC class I
complex are 8 to 10-mers, the epitopes used can comprise
fragments of bovine viral proteins. In one embodiment,
epitopes comprise peptides of between 5 and 25 amino acids
in length. In another embodiment, epitopes comprise pep
tides of between 5 and 15 amino acids in length. In yet
another embodiment, epitopes comprise peptides of between
8 and 10 amino acids in length.
0044) The preparation can be administered to any animal

which can become infected with a bovine virus. In one

embodiment, the animal is a ruminant animal, more prefer
ably a Bovidae and more preferably still a member of the
genus BOS.
004.5 The animal can be administered complexes com
prising a single epitope complexed to HSPS or can be
administered complexes comprising multiple epitopes com
plexed to HSPs. The epitope/HSP complexes can be admin
istered in a single dose or the initial dose can be followed by
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one or more booster doses. If more than one epitope is used,
then all epitopes can be given in each administration or,
alternatively, different epitope/HSP complexes can be given
at each administration.

0046) The complexes of the present invention can be
administered by a variety of routes and methods. Suitable
routes and methods of administration include orally,
parenterally, by inhalation Spray, rectally, intradermally,
transdermally, or topically in dosage unit formulations con
taining conventional nontoxic pharmaceutically acceptable
carriers, adjuvants, and vehicles as desired. The term
parenteral as used herein includes Subcutaneous, intrave
nous, intramuscular, or intrasternal injection, or infusion
techniques. In one embodiment, the complexes are admin
istered by injection and more particularly by intramuscular
injection. In another embodiment, the complexes are admin
istered by an intra nasal inhalation spray. In yet another
embodiment, the complexes can be administered by multiple
routes, as for example is taught in U.S. Pat. No 5,462,734.
Methods for the formulation of drugs is well known in the
art and is discussed in, for example, Hoover, John E.,
Remington's Pharmaceutical Sciences, Mack Publishing

Co., Easton, Pa. (1975), and Liberman, H. A. and Lachman,

L., Eds., Pharmaceutical Dosage Forms, Marcel Decker,

New York, N.Y. (1980).
0047 Injectable preparations, for example, sterile inject
able aqueous or oleaginous Suspensions, can be formulated
according to the known art using Suitable dispersing or
wetting agents and Suspending agents. The Sterile injectable
preparation may also be a sterile injectable Solution or
Suspension in a nontoxic parenterally acceptable diluent or
Solvent, for example, as a Solution in 1,3-butanediol. Among
the acceptable vehicles and Solvents that may be employed
are water, Ringer's Solution, and isotonic Sodium chloride
Solution. In addition, Sterile, fixed oils are conventionally
employed as a Solvent or Suspending medium. For this
purpose, any bland fixed oil may be employed, including
Synthetic mono- or diglycerides. In addition, fatty acids Such
as oleic acid are useful in the preparation of injectables.
Dimethyl acetamide, Surfactants including ionic and non
ionic detergents, and polyethylene glycols can be used.
Mixtures of Solvents and wetting agents Such as those
discussed above are also useful.

0.048 Suppositories for rectal administration of the com
pounds discussed herein can be prepared by mixing the
active agent with a Suitable non-irritating excipient Such as
cocoa butter, Synthetic mono-, di-, or triglycerides, fatty
acids, or polyethylene glycols which are Solid at ordinary
temperatures, but liquid at the rectal temperature, and which
will therefore melt in the rectum and release the complex.
0049 Solid dosage forms for oral administration may
include capsules, tablets, pills, powders, and granules. In
Such Solid dosage forms, the compounds of this invention
are ordinarily combined with one or more adjuvants appro
priate to the indicated route of administration. If adminis
tered per OS, the compounds can be admixed with lactose,
Sucrose, Starch powder, cellulose esters of alkanoic acids,
cellulose alkyl esters, talc, Stearic acid, magnesium Stearate,
magnesium oxide, Sodium and calcium Salts of phosphoric
and Sulfuric acids, gelatin, acacia gum, Sodium alginate,
polyvinylpyrrolidone, and/or polyvinyl alcohol, and then
tableted or encapsulated for convenient administration. Such
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capsules or tablets can contain a controlled-release formu
lation as can be provided in a dispersion of active compound
in hydroxypropylmethyl cellulose. In the case of capsules,
tablets, and pills, the dosage forms can also comprise
buffering agents Such as Sodium citrate, or magnesium or
calcium carbonate or bicarbonate. Tablets and pills can
additionally be prepared with enteric coatings.
0050 For therapeutic purposes, formulations for
parenteral administration can be in the form of aqueous or
non-aqueous isotonic Sterile injection Solutions or Suspen
Sions. These Solutions and Suspensions can be prepared from
Sterile powders or granules having one or more of the
carriers or diluents mentioned for use in the formulations for

oral administration. The compounds can be dissolved in
water, polyethylene glycol, propylene glycol, ethanol, corn
oil, cottonseed oil, peanut oil, Sesame oil, benzyl alcohol,
Sodium chloride, and/or various buffers. Other adjuvants and
modes of administration are well and widely known in the
pharmaceutical art.
0051 Liquid dosage forms for oral administration can
include pharmaceutically acceptable emulsions, Solutions,
Suspensions, Syrups, and elixirs containing inert diluents
commonly used in the art, Such as water. Such compositions
can also comprise adjuvants, Such as wetting agents, emul
Sifying and Suspending agents, and Sweetening, flavoring,
and perfuming agents.
0052 The amount of epitope/HSP complex that can be
combined with the carrier materials to produce a single
dosage form will vary depending upon the patient or animal
and the particular mode of administration.
0053 Any suitable method known in the art can be used
to obtain the bovine viral epitopes or HSPs used in the
present invention. In general, three methods can be used. In
one method, the bovine viral epitopes and/or HSPs can be
isolated from cells which naturally produce the epitopes or
HSPs. For example, suitable susceptible host cells can be
infected with the virus of interest and the cells grown in
culture. In one method, virus is then isolated from the host

cells and the epitopes isolated from the virus. The isolated
Virus is treated with a detergent to release the glycoproteins
located within the lipid envelop of the virion. Alternatively,
glycoprotein epitopes present on the Surface of infected cells
can be obtained by detergent-solubilized lysates of infected
cells rather than from whole virions. The proteins are then
Separated from the detergent and other debris and the
individual protein epitopes isolated by methods well known
to those of ordinary skill in the art.
0054 Glycoprotein 96 can be purified from any cell that
naturally expresses the protein. The gp96 can be isolated
from tissues collected in Vivo or can be from cells grown in
vitro. If obtained from in vitro cell culture, conditions can be

manipulated, for example increased temperature, to induce
increased production of gp96. Various methods for obtaining
proteins from cells and tissue are known to those of skill in
the art. These include precipitation by, for example, ammo
nium Sulfate or ethanol precipitation, acid extraction, anion
or cation eXchange chromatography, phosphocellulose chro
matography, hydrophobic interaction chromatography,
affinity chromatography, hydroxylapatite chromatography,
lectin chromatography, high performance liquid chromatog

raphy (HPLC), electrophoresis under native or denaturing
conditions, isoelectric focusing, and immunoprecipitation.
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0055. In one embodiment, gp96 is isolated from liver
cells using the method described by Srivastava, Methods,
12:165-171, 1997. Briefly, liver cells are homogenized in a
solution of 30 mM sodium bicarbonate, pH 7, and 1 mM

phenylmethane-Sulphonyl fluoride (PMSF) using a

mechanical homogenizer Such as a Polytron. The lysate is
centrifuged at 2000 g and 4 C. to remove cellular debris.
The Supernatant is re-centrifuged at 100,000 g for 90 min
utes at 4 C. Gp96 can be isolated either from the pellet or
Supernatant from this centrifugation. Purification of gp96
from the Supernatant is accomplished by bringing the Super
natant to 50% ammonium sulfate and stirring for 2 to 12
hours at 4 C. followed by centrifugation at 6000 rpm in a
SS34 rotor. The Supernatant from this centrifugation is
brought to 70% ammonium sulfate and centrifuged as for the
50% cut. The resulting pellet is washed in PBS containing
70% ammonium Sulfate and then dissolved in 10 volumes of

PBS containing 2 mM each Ca" and Mg" (Ca/Mg PBS).
Any undissolved material is removed by centrifugation. The
dissolved Solution is then added to a concanavalin A chro

matography column and the bound proteins eluted with 10%
C-D-methyl mannoside dissolved in Ca/Mg PBS. One third
of the column volume is applied to the column after which
the column is sealed and incubated at 37 C. for 30 minutes.

Following this incubation, five column volumes of eluant
are applied and the fractions collected. Protein containing
fractions are then applied to a DEAE ion exchange column
and the proteins eluted with five volumes of 700 mM NaCl,
5 mM sodium phosphate, pH 7. For purification of gp96
from the 100,000 g pellet, the pellet is suspended in 5
volumes of PBS containing 0.1% octy glucopyranoside and
placed on ice for 1 hour. The Suspension is then centrifuged
at 20,000 g for 30 minutes at 4 C. and the detergent
removed by dialysis against PBS or other suitable method.
The resulting solution is centrifuged at 100,000 g for 90
minutes and calcium and magnesium are added to the
Supernatant to a final concentration of 2 mM each. Further
purification is carried out as previously described.
0056. In a second method, epitopes and/or HSPs can be
made by recombinant DNA technology. Once the nucleotide
Sequence encoding the viral epitope or HSP of interest is
known, it can be placed into an expression vector and used
to transfect a suitable host cell by methods commonly
known to those of ordinary skill in the art. Sambrook et al.,
Molecular Cloning, A Laboratory Manual, 2, Ed., Cold

Spring Harbor Press, (1989) and Ausubel et al., Short
Protocols in Molecular Biology, 2, Ed., John Wiley & Sons

(1992). Suitable expression vectors include chromosomal,

non-chromosomal and Synthetic DNA sequences, for
example, SV 40 derivatives, bacterial plasmids, phage
DNA; baculovirus; yeast plasmids; vectors derived from
combinations of plasmids and phage DNA; and viral DNA
Such as Vaccinia, adenovirus, fowl pox virus, and pseudo
rabies. In addition, any other vector that is replicable and
viable in the host may be used.
0057 The nucleotide sequence of interest may be
inserted into the vector by a variety of methods. In the most
common method, the Sequence is inserted into an appropri

ate restriction endonuclease site(s) using procedures com
monly known to those skilled in the art and detailed in, for
example, Sambrook et al., Molecular Cloning, A Laboratory

Manual, 2, Ed., Cold Spring Harbor Press, (1989) and
Ausubel et al., Short Protocols in Molecular Biology, 2.

Ed., John Wiley & Sons (1992).

0058. In an expression vector, the sequence of interest is
operably linked to a Suitable expression control Sequence or
promoter recognized by the host cell to direct mRNA
Synthesis. Promoters are untranslated Sequences located

generally 100 to 1000 base pairs (bp) upstream from the start

codon of a structural gene that regulate the transcription and
translation of nucleic acid Sequences under their control.
Promoters are generally classified as either inducible or
constitutive. Inducible promoters are promoters that initiate
increased levels of transcription from DNA under their
control in response to Some change in the environment, e.g.
the presence or absence of a nutrient or a change in tem
perature. Constitutive promoters, in contrast, maintain a
relatively constant level of transcription.
0059 A nucleic acid sequence is operably linked when it
is placed into a functional relationship with another nucleic
acid Sequence. For example, DNA for a presequence or
Secretory leader is operatively linked to DNA for a polypep
tide if it is expressed as a preprotein which participates in the
Secretion of the polypeptide; a promoter is operably linked
to a coding Sequence if it affects the transcription of the
Sequence; or a ribosome binding site is operably linked to a
coding Sequence if it is positioned So as to facilitate trans
lation. Generally, operably linked Sequences are contiguous
and, in the case of a Secretory leader, contiguous and in
reading phase. Linking is achieved by ligation at restriction
enzyme Sites. If Suitable restriction sites are not available,
then Synthetic oligonucleotide adapters or linkers can be

used as is known to those skilled in the art. Sambrook et al.,

Molecular Cloning, A Laboratory Manual, 2, Ed., Cold
Spring Harbor Press, (1989) and Ausubel et al., Short
Protocols in Molecular Biology, 2, Ed., John Wiley & Sons
(1992).
0060 Common promoters used in expression vectors
include, but are not limited to, LTR CMV or SV40 promoter,
the E. coli lac or trp promoters, and the phage lambda PL
promoter. Other promoters known to control the expression
of genes in prokaryotic or eukaryotic cells can be used and
are known to those skilled in the art. Expression vectors may
also contain a ribosome binding site for translation initia
tion, and a transcription terminator. The vector may also
contain Sequences useful for the amplification of gene
expression.
0061 Expression vectors can, and usually do, contain a
Selection gene or Selection marker. Typically, this gene
encodes a protein necessary for the Survival or growth of the
host cell transformed with the vector. Examples of suitable
markers include dihydrofolate reductase (DHFR) or neomy
cin resistance for eukaryotic cells, and tetracycline or ampi
cillin resistance for E. coli.

0062. In addition, expression vectors can also contain
marker Sequences operatively linked to a nucleotide
Sequence for a protein that encode an additional protein used
as a marker. The result is a hybrid or fusion protein com
prising two linked and different proteins. The marker protein
can provide, for example, an immunological or enzymatic
marker for the recombinant protein produced by the expres
Sion vector. Numerous Suitable vectors are commercially
available and are known to those of ordinary skill in the art.
0063. Once an expression vector has been constructed it
is placed into a suitable host cell. The host cell will vary with
the vector used, but in general can be a higher eukaryotic
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cell, Such as a mammalian cell, or a lower eukaryotic cell
Such as a yeast cell, or the host can be a prokaryotic cell Such
as a bacterial cell. Introduction of the construct into the host

cell can be accomplished by a variety of methods including
calcium phosphate transfection, DEAE-dextran mediated
transfection, Polybrene, protoplast fusion, liposomes, direct
microinjection into the nuclei, Scrape loading, and electropo
ration.

0.064 Once transfected host cells are selected based on
expression of the Sequences encoded by the vector. Selected
host cells are then grown in culture and induced to produce
the protein of interest. If the host cell Secretes the protein
into the culture medium, then the protein can be purified
from the medium. If the protein is not secreted, the host cells
can be harvested, lysed and the protein collected from the
lysate. Proteins can be purified from the cell medium or
lysate by any Suitable method, Such as those previously
discussed.

0065. The vector can be constructed so as to produce a
Single protein of interest or Several proteins. For example, a
fusion protein of Several bovine viral epitopes can be
constructed. The resulting protein can be used as a fusion
protein or be constructed Such that the epitopes can be
Separated, for example, by enzymatic cleavage.
0066. A third method for the production of BHV 1
epitopes or HSP is by chemical synthesis. Any method of
peptide Synthesis can be used to practice the present inven
tion. Chemical Synthesis of peptides is well known to those

of ordinary skill in the art (Bodanszky, Principles of Peptide

Synthesis, Springer-Verlag, 1993; Atherton and Sheppard,
Solid Phase Peptide Synthesis. A Practical Approach, IRL
Press, 1989; Bodanszky and Bodanszky, The Practice of

peptide Synthesis, Springer-Verlang, 1984). Modern solid

phase peptide Synthesis involves the creation of a linear
peptide chain by the Successive addition of amino acids to a
growing peptide whose C terminus is covalently linked to a
Solid Support or resin. Solid-phase peptide Synthesis entails
three repeated reactions, deprotection, activation, and cou
pling. In order to prevent unwanted reactions at their alpha
and Side-chain functionalities, amino acids used in peptide
synthesis are derivatized or “protected.” Commonly used
amino protecting groups include the t-butoxycarbonyl group

(Boc), 9-fluorenylmethyloxycarbonyl (Fmoc), 2-(4biphenylyl)propyl(2)oxycarbonyl (Bpoc), 2-ntiro-phenyl
Sulfenyl (Nps), and dithia-Succionyl (Dts). During the depro
tection Step, the protecting group is removed to make the
alpha-amino group on the end of the growing peptide chain
available. Activation converts the next amino acid to be

added into an active ester. During coupling, an amide bond
is formed between the active ester and the deprotected
alpha-amino group. The process is repeated until the desired
peptide is formed. When Synthesis is completed, the Side
chain protecting groups are removed and the peptide cleaved
from the Solid phase. In one preferred embodiment, bovine
Viral epitopes are made by Solid phase peptide Synthesis
using Standard Fmoc chemistry.
0067 Viral epitopes useful in the practice of the present
invention preferably are capable of binding to a heat shock
protein. Several methods are available to determine binding.
One method for determination of binding is that used by
Blachere et al., J. Exp. Med., 186:1315-1322, 1997. In
general, the epitope to be tested is coupled to a detection
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moiety. Numerous detection moieties will be readily appar
ent to those of ordinary skill in the art and include, without
limitation, radioactive labels, Such as radionuclides, fluoro

phores or fluorochromes, peptides, enzymes, antigens, anti

bodies, Vitamins or Steroids. In one embodiment, the detec

tion moiety is a radionuclide, preferably 'I. The epitope to

be tested is then incubated with a heat shock protein under
conditions which promote binding of the epitope to the heat
Shock protein. In one embodiment, binding is conducted at
room temperature for 30 minutes in a binding buffer com
prising 20 mM HEPES, pH 7, 20 mM NaCl and 2 mM
MgCl2. After the binding reaction, bound and unbound
labeled epitopes are separated by any Suitable means, for
example, ultrafiltration or column chromatography. The
amounts of bound and unbound labeled epitope are then
determined, Such as in one embodiment, by quantitative
autoradiography to determine the amount of binding. It will
be apparent to those skilled in the art, that Screening for
binding can also be accomplished by using a labeled heat
Shock protein rather than a labeled epitope. Also, it may be
possible to determine binding without the use of a label
coupled to one of the proteins by conducting a binding
reaction and then Separating the reaction products, by for
example SDS-PAGE electrophoresis and staining. The bind
ing of the epitope to the heat shock protein will result in a
band of increased molecular weight.
0068. In the present invention, an immune response to a
Viral epitope is achieved by administration of the epitope in
combination with a heat Shock protein. In one embodiment,
the heat shock protein is gp96. The heat shock protein can
be bound to the epitope by any method known in the art. The
binding reaction can be conducted in vitro by the method
described by Blachere et al., J. Exp. Med., 186:1315-1322,
1997, and discussed above. When the HSP/epitope complex
is formed in vitro, the ratio of epitope to HSP used to form
the complex can vary over a wide range. In one embodiment,
the ratio of epitope to HSP is one part epitope to 100 to
100,000 parts HSP. In another embodiment, the ratio is one
part epitope to 1,000 to 50,000 parts HSP. In yet another
embodiment, the ratio is one part epitope to 10,000 to 25,000
parts HSP and in still another embodiment, the ratio is one
part epitope to 12,500 parts HSP.
0069. Alternatively the epitope-HSP complex can be
produced in cells. In this embodiment, a host cell that
expresses a heat shock protein is transfected with a vector
containing a nucleotide Sequence encoding the viral protein
or epitope of interest. Methods for producing expression
vectors and for transforming host cells have been discussed
previously. Transformed cells are induced to express both
the endogenous heat Shock protein and the exogenous viral
epitope. The cells are then harvested, lysed and the epitope
HSP complexes isolated using Standard protein purification
techniques Such as those previously discussed.
0070 The ability of epitope/HSP complexes to elicit
cytotoxic T lymphocytes can be determined, for example, by

the 'Cr release assay. Methods for conducting this assay are

known to those of ordinary skill in the art and can be found,
for example, in Zatechka et al., Vaccine, 17:686-694, 1999
and Stikovsky and Henkart, eds., Cytotoxic Cells, Birkauser,
1993. To generate cytotoxic T lymphocytes, animals are
twice administered at 1 to 3 week intervals, the candidate

epitope/HSP complex, the HSP protein alone or the epitope
alone. Five to ten days after the Second administration, the
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animals are euthanized and the Spleens collected. Lympho
cytes are isolated by any Suitable method, for example, by
use of a Percoll gradient. Lymphocytes are restimulated in
Vitro with peptide epitope pulsed, naive, Syngeneic, Stimu
lator lymphocytes. Stimulator lymphocytes can be prepared,
for example, by pulsing with from 10 to 200 tug/ml of
epitope for 1 hour at 37 C. in any suitable culture medium,
for example, RPMI-1640 Supplemented with 10% fetal
bovine Serum. In one preferred embodiment, Stimulator
lymphocytes are pulsed with 100 lug/ml of epitope. The
pulsed stimulator lymphocytes are irradiated with 2000 Rad.
Any Suitable Source of radiation can be used. In one embodi

ment, a 'CO irradiator is used. Responders and stimulators
are co-cultured at 2x10 cells of each type at 37° C. in an

appropriate culture medium.
0071 Target cells are pulsed with candidate epitopes,
either alone or in combination, as described above for the

generation of cytotoxic T lymphocytes. Pulsed and non

pulsed target cells are labeled with 100 uCi of Cr per
1x10 cells for one hour at 37 C. Labeled cells are then

washed and incubated at different effector:target cell ratios,
usually ranging from 1:1 to 100:1 for 4 to 6 hours in a
suitable culture medium, for example RPMI-1640 contain
ing 5% fetal bovine Serum. Each assay point is preformed in
duplicate or triplicate, and appropriate controls to measure

spontaneous 'Cr release (no lymphocytes (effectors) added)

and 100% release (lysed target cells). Lysis of target cells

can be accomplished, for example, by use of a detergent. In
one embodiment, target cells are lysed by treatment with
0.5% Triton-X100. Target lysis is determined by measuring

0075). Gp96
0076 Heat shock protein gp96 is obtained from liver
cells. The procedure used is that described previously.
Briefly, liver tissue is homogenized in a solution of 30 mM
Sodium bicarbonate, pH 7, and 1 mM phenylmethane
sulphonyl fluoride (PMSF), centrifuged and the protein in
the Supernatant precipitated with 50% and 70% ammonium
sulfide. The precipitate from the 70% ammonium sulfate cut
is washed, resuspended and further purified by concanavalin
A and DEAE chromatography. The gp96 is stored in phos
phate buffered, pH 7, 700 mM NaCl at -80° C.
0.077 Gp96/Epitope Binding
0078. The peptide binding is carried out as previously
described. Two ng of each epitope peptide is mixed with 25
lug of gp96 and incubated at 60° C. for 10 minutes in peptide
binding buffer (20 mM HEPES, pH 7, 20 mM NaCl, 2 mM
MgCl) to dissociate endogenous liver peptides bound to the
gp96 molecule. The temperature is then lowered to room
temperature followed by an additional incubation for 30
minutes to bind the epitope peptides to the gp96. A control
complex is made in which bovine serum albumin (BSA)
replaces the gp96 protein.
0079 Immunization and Generation of Cytotoxic T Lym
phocytes
0080 Animals are immunized subcutaneously with gp96/

the amount of Cr in a sample of the culture medium using

epitope complex (25 uggp96/2ng epitope), gp96 alone (25
pig), epitope peptide alone (2 ng) in 200 ul, or BSA/epitope
complex (25 ug BSA/2 ng epitope). Animals are given two

follows:

injections Spaced one week apart. One week following the
last injection, the Spleen is collected and lymphocytes iso

a gamma counter. The percent Specific lysis is calculated as

lated.

sample 'Cr release -w

% specific lysis =

spontaneous Cr release
maximum Cr release - x 100

spontaneous 5 Cr release

0081 Lymphocytes are restimulated in vitro with the
epitope peptide pulsed (100 ug/ml) naive, Syngeneic stimu
lator cells. Stimulator cells are prepared by pulsing with 100
tug/ml of the epitope peptides in T-cell culture medium

(RPMI-1640, 2 mM L-glutamine, 0.1 mM MEM nonessen
tial amino acids, 2.85 g/l NaHCO, 1 mM sodium pyruvate,

EXAMPLES

0.072 The following examples are intended to provide
illustrations of the application of the present invention. The
following examples are not intended to completely define or
otherwise limit the scope of the invention.
Example 1
Generation of gp96/Epitope Complexes
0073 Epitopes
0.074 Epitope peptides are selected to contain ASPMs or
Supermotifs for the Species in which they are to be injected.
Epitope peptides are Synthesized using Standard F-moc Solid
phase chemistry and purified. If desired, the Sequence of the
epitope peptides can be confirmed by fast atom bombard
ment-mass Spectrum analysis. Epitope peptides are dis
solved in distilled water at 2 mg/ml and stored at -70° C.
until used.

10 mM HEPES, 50 uM 2-mercaptoethanol, 10% FBS) for 1
hour at 37 C. in a 5% CO2 atmosphere. The pulsed

stimulator cells are then irradiated (2000 Rad) with a 'Co
irradiator. Responder and Stimulator cells are co-cultured at
2x10" cells of each cell type in 25 cm culture flasks in T-cell

culture medium at 37 C. in a atmosphere of 5% CO.

0082

'Cr Release Cytotoxicity Assay

0083) Syngeneic target cells are pulsed with either the
epitope peptides (100 lug/ml) for 1 hour at 37° C. in 5% CO.
Pulsed and non-pulsed target cells are labeled with 100 uCi

of NaCrO per 1x10° cells for 1 hour. Labeled cells are

washed with RPMI-1640 containing 5% FBS and incubated
at effector:target ratios of 10:1, 20:1, 40:1 and 8.0:1 for 5
hours. Target cell lysis is measured by counting 100 ul of
culture medium in an automated gamma counter. The per
cent specific lysis is calculated as previously described.
Spontaneous release is calculated using culture medium
from Wells containing target cells alone. Maximum release
is calculated using culture medium from Wells in which the
cells add been lysed by 0.5% Triton-X100.
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Example 2
Cytotoxic T Lymphocyte Recognition in Infected
Target Cells
0084. The cytotoxicity assays of Example 1 is conducted
with targets pulsed with epitope peptides. To confirm that the
results are applicable to virus infected cells, the cytotoxicity
assay of Example 1 is repeated with either virus infected or
mock infected target cells. For mock infection, culture
medium without virus is used. The assay is performed at an
effector to target ratio of 20:1.
Example 3
Induction of Cytotoxic T-lymphocytes Using
gp96/epitope Complexes Generated In Cells
0085 Production of Bovine Viral Epitope Expressing
Cells

0.086 BC10ME cells (mouse embryo fibroblasts, H-2)

are transfected with a Moloney murine retrovirus vector
containing a gene encoding a viral protein or the B-galac
tosidase gene to yield BC-Pr or BC-Bgal cells. These cells
constitutively express either a bovine viral epitope protein or
B-galactosidase along with gp96. The transfected cells are
maintained in Dulbecco's Modified Eagle's Medium

that last immunization, blood Samples are collected, the
plasma separated and presence of viral epitope gld antibod

ies detected by a radioimmunoassay (RIA).
Example 5
In vitro Stimulation of Naive Bovine Splenocytes
with gp96-Epitope Complexes
O095 In vitro Stimulation

0.096 Peripheral blood mononuclear cells (PBMCs) are
isolated from naive calves. PBMCs are stimulated in vitro

with gp96 derived from BC-Pr cells. Production of BC-Pr
cells and isolation of gp96 from BC-Pr cells is described in
Example 3. Cells are Stimulated by adding 25 ug of gp96

from BC-Pr cells per 1x10 bovine PBMCs in a volume of

1 ml of T cell culture medium (RPMI-1640, 10% FBS)
followed by a 1 hour incubation at 37 C. Following
stimulation, cells are resuspended in 50 ml of T-cell culture

medium, divided among five, 25 cm tissue culture flasks
and cultured for Six dayS. At the end of the Six day culture
period, a 'Cr release cytotoxicity assay is performed as
described in Example 1. Effector cells are in vitro stimulated
PBMCs and target cells are either virus infected or mock
infected autologous PBMCs. Effector to target cell ratios are
10:1, 20:1, 40:1 and 8.0:1.

(DMEM) containing 4.5 mg/ml glucose, 10% fetal bovine

serum, 1 mM sodium pyruvate, 2 mM glutamate, 100 U/ml

each of penicillin and streptomycin at 37° C. in a 5% CO
atmosphere.
0087 Isolation of Viral Epitope/gp96 Complexes
0088 Cells are lysed in four volumes of a solution of 30
mM sodium bicarbonate, pH 7, and 1 mM phenylmethane
sulphonyl fluoride (PMSF) using a mechanical homog
enizer. Complexes are isolated by ammonium Sulfate pre
cipitation, concanavalin A chromatography, and DEAE
chromatography as described in Example 1.
0089) Immunization and Generation of Cytotoxic T Lym
phocytes

0090. Female BALB/c (ByJ) mice (H-2'), 8-12 weeks of

age, are given two Subcutaneous injections of 25ug of gp96
isolated from BC-Pr or BC-Bgal cells. The injections are
given one week apart. Eight days after the Second injection,
the mice are euthanized, and Spleenocytes collected and
restimulated in vitro with BC-Pr cells using the methods
described in Example 1.

0091 Cr Release Cytotoxicity Assay
0092 Five to seven days after restimulation, Cr cyto

toxicity assays are conducted according to the method
described in Example 1 using BC-Pr and BC-Bgal cells as
the targets.
Example 4
Induction of a Humoral Immune Response by
gp96/Epitope Complexes
0093) Immunization
0094. Animals are immunized with two subcutaneous
injections of 25 lug of BHV 1 g)/gp96 complex isolated
from BC-Pr cells as described in Example 3. Eight days after

Conclusion

0097. In light of the detailed description of the invention
and the examples presented above, it can be appreciated that
the Several aspects of the invention are achieved.
0098. It is to be understood that the present invention has
been described in detail by way of illustration and example
in order to acquaint otherS Skilled in the art with the
invention, its principles, and its practical application. Par
ticular formulations and processes of the present invention
are not limited to the descriptions of the Specific embodi
ments presented, but rather the descriptions and examples
should be viewed in terms of the claims that follow and their

equivalents. While Some of the examples and descriptions
above include Some conclusions about the way the invention
may function, the inventor does not intend to be bound by
those conclusions and functions, but puts them forth only as
possible explanations.
0099] It is to be further understood that the specific
embodiments of the present invention as Set forth are not
intended as being exhaustive or limiting of the invention,
and that many alternatives, modifications, and variations
will be apparent to those of ordinary skill in the art in light
of the foregoing examples and detailed description. Accord
ingly, this invention is intended to embrace all Such alter
natives, modifications, and variations that fall within the

Spirit and Scope of the following claims.
What is claimed is:

1. A method of eliciting an immune response against a
bovine virus comprising, combining at least one bovine viral
epitope and at least one heat Shock protein to form a purified
epitope/heat Shock protein complex, and administering an
immune System Stimulating amount of Said purified epitope
heat Shock protein complex to an animal.
2. The method of claim 1 wherein said bovine viral

epitope further comprises a Supermotif.
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epitope further comprises an allele Specific peptide motif.
4. The method of claim 3 wherein said allele specific
peptide motif is Selected from the group consisting of

23. The composition of claim 22, wherein said bovine
Viral epitope further comprises a Supermotif.
24. The composition of claim 22, wherein said bovine
Viral epitope further comprises an allele Specific peptide

BoLA-A11, BoLA-A20, BoLA-HD1, BoLA-HD6 and

motif.

BOLA-HD7.

25. The composition of claim 24, wherein said allele
Specific peptide motif is Selected from the group consisting

3. The method of claim 1 wherein said bovine viral

5. The method claim 1, wherein said bovine viral epitope
is between 5 and 25 amino acids in length.
6. The method of claim 1, wherein said bovine viral

epitope is between 5 and 15 amino acids in length.
7. The method of claim 1, wherein said viral epitope is
between 8 and 10 amino acids in length.
8. The method of claim 1 wherein said epitope is from a
Virus Selected from the group consisting of bovine viral
diarrhea virus, bovine respiratory Syncytial virus, parainflu
enza virus III, bovine corona virus, and bovine rota Virus.

9. The method of claim 1 wherein said heat shock protein
is selected from the group consisting of HSP60, HSP 70 and
HSP 90 families.

10. The method of claim 9 wherein said heat shock protein
is gp96
11. The method of claim 1 wherein said heat shock protein
is a heterologous heat Shock protein.
12. The method of claim 1 wherein said heat shock protein
is a homologous heat shock protein.
13. The method of claim 1 wherein said epitope/heat
Shock protein complex is formed in vitro.
14. The method of claim 1 wherein said epitope/heat
Shock protein complex is formed in Vivo.
15. The method of claim 1 wherein said epitope is a
recombinant epitope
16. The method of claim 1 wherein said epitope is a
Synthetic peptide
17. The method of claim 16, wherein said synthetic
peptide is Synthesized by Solid phase chemistry.
18. The method of claim 1 wherein said animal is a
ruminant.
19. The method of claim 18 wherein said ruminant is a
Bovidae.
20. The method of claim 19 wherein said Bovidae is of the

genus BoS.
21. A method for eliciting an immune response to a bovine
Virus comprising, combining at least one bovine virus allele
Specific peptide motif containing epitope of at least 8-10
amino acids long and a heat shock protein gp96 to form a
purified epitope/heat shock protein complex, and adminis
tering an immune System Stimulating amount of Saidpurified
epitope-heat Shock protein complex to a ruminant.
22. A composition comprising, a purified epitope/heat
Shock protein complex containing at least one bovine virus
epitope complexed with at least one heat shock protein, and
a pharmaceutically acceptable carrier, diluent or excipient.

of BoLA-A11, BoLA-A20, BoLA-HD1, BoLA-HD6 and
BOLA-HD7.

26. The composition claim 22, wherein the bovine viral
epitope is between 5 and 25 amino acids in length.
27. The composition of claim 22, wherein the bovine viral
epitope is between 5 and 15 amino acids in length.
28. The composition of claim 22, wherein the bovine viral
epitope is between 8 and 10 amino acids in length.
29. The composition of claim 22 wherein said epitope is
from a virus Selected from the group consisting of bovine
Viral diarrhea virus, bovine respiratory Syncytial virus,
parainfluenza virus III, bovine corona virus, and bovine rota
Virus.

30. The composition of claim 22, wherein said heat shock
protein is selected from the group consisting of HSP60, HSP
70 and HSP 90 families.

31. The composition of claim 30 wherein said heat shock
protein is gp96
32. The composition of claim 22, wherein said heat shock
protein is a heterologous heat Shock protein.
33. The composition of claim 22, wherein said heat shock
protein is a homologous heat shock protein.
34. The composition of claim 22, wherein Said epitope/
heat shock protein complex is formed in vitro.
35. The composition of claim 22 wherein said epitope/
heat Shock protein complex is formed in Vivo.
36. The composition of claim 22 wherein said epitope is
a recombinant epitope
37. The composition of claim 22 wherein said epitope is
a Synthetic peptide.
38. The composition of claim 37 wherein the synthetic
peptide is Synthesized by Solid phase chemistry.
39. A composition comprising, a purified epitope/heat
Shock protein complex containing:
a gp96 heat shock protein;
at least bovine Viral epitope of 8-10 amino acids long, Said
epitope being from a virus Selected from the group
consisting of bovine viral diarrhea virus, bovine respi
ratory Syncytial virus, parainfluenza virus III, bovine
corona virus, and bovine rota Virus, and

a pharmaceutically acceptable carrier, diluent or exci
peint.

